IBD Competition Will Limit Pipeline Progress Despite Early Promise
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 10 Analysts
Published
07 Aug 25
Updated
16 Aug 25
AnalystLowTarget's Fair Value
US$8.67
11.4% undervalued intrinsic discount16 Aug
US$7.68
1Y
-52.7%7D
6.2%